Try our Advanced Search for more refined results

Skelaxin (Metaxalone) Antitrust Litigation

  1. January 30, 2014

    Class Cert. Denied In Pfizer Pay-For-Delay Suit

    A Tennessee federal judge on Thursday refused to grant class certifications to two groups claiming Pfizer Inc.'s King Pharmaceuticals Inc. settled a patent dispute with a deal to keep muscle relaxant Skelaxin off the market in a pay-for-delay arrangement that kept the drug prices at brand-name levels.

  2. September 10, 2013

    Pfizer Denied Interlocutory Appeal In Pay-For-Delay MDL

    A Tennessee federal judge Tuesday rejected a bid by Pfizer Inc.'s King Pharmaceuticals LLC and Mutual Pharmaceutical Co. to appeal his finding that antitrust claims accusing them of blocking the release of a generic version of the drug Skelaxin were exempt from the statute of limitations.

  3. January 09, 2013

    Rite Aid, Others Jump Into Pay-For-Delay MDL Against Pfizer

    Rite Aid Corp. and others sued Pfizer Inc.'s King Pharmaceuticals Inc. in Tennessee federal court Friday, joining multidistrict litigation that alleges King settled a patent dispute with a deal to keep generic Skelaxin off the market, raising the muscle relaxant's price.

  4. January 07, 2013

    King Pharma Says Patent Deal Didn't Bar Skelaxin Generic

    Pfizer Inc. unit King Pharmaceuticals Inc. on Friday said that, contrary to complaints, a patent licensing agreement related to its Skelaxin drug, now the subject of multidistrict antitrust litigation in Tennessee, didn't prevent a generic version of the muscle relaxant from coming to market.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!